Key Takeaways from Chromadex / Oppenheimer Meeting CDXC

Last week, Chromadex (ticker: CDXC) CEO Rob Fried and CFO Kevin Farr met with Oppenheimer analyst Brian Nagel in NYC. The following are Nagel's key takeaways:

• Overall, management indicates that the company continues to work to build a larger and more robust operational infrastructure so as to better support increasingly significant sales of core products Tru Niagen and Niagen.

• Management is quite upbeat following recent regulatory approvals in Europe and Australia and is forging partnerships with leading distributors in these markets.

• The company’s strategic relationship with Nestlé continues to take shape; management is optimistic that Nestlé products enhanced by Tru Niagen should begin selling in the next several quarters.

• CDXC does not disclose repeat rates explicitly, but indicates that follow-on sales to customers that take Tru Niagen for longer than a month track decidedly high.

• While the timing of any resolution to ongoing legal actions between CDXC and a competitor is still unknown, management indicates that it looks forward to presenting its initial claims in court in mid-May.

ABOUT: I'm one of the core group who built SeekingAlpha.com. I focused on product development. More HERE.

NOTE: This website is published for informational purposes only and does not provide investment advice, nor is it an offer or solicitation of any kind to buy or sell any securities and/or investment products. In the event I invested in a featured security or investment product, an acknowledgment will be made. All opinions expressed are my own.